Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tienilic acid is a small molecule loop diuretic with uricosuric (uric-acid lowering) action. It was formerly marketed under the brand name Selacryn for the treatment of hypertension and hyperuricaemia. Its mechanism of action involves inhibition of sodium reabsorption in the cortical diluting segment of the distal nephron in the kidney. Tienilic acid also acts as a mechanism-based inhibitor (suicide substrate) of cytochrome P450 enzyme CYP2C9. The drug was withdrawn from markets due to reports linking it to hepatotoxicity and hepatitis[1][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tienilic acid.